<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919412</url>
  </required_header>
  <id_info>
    <org_study_id>101436-3</org_study_id>
    <secondary_id>07009</secondary_id>
    <nct_id>NCT00919412</nct_id>
  </id_info>
  <brief_title>Non Invasive Biomarkers to Identify Subjects at Risk for Preterm Delivery</brief_title>
  <acronym>PTMARKER</acronym>
  <official_title>Non-Invasive Biomarkers To Identify Subjects At Risks For Preterm Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to identify a non-invasive predictor or predictors that will&#xD;
      increase the clinician's ability to identify patients with preterm labor (PTL) at risk for&#xD;
      preterm delivery (PTD). Through these studies we also hope to reveal potential therapeutic&#xD;
      targets in the prevention of prevention of preterm births.&#xD;
&#xD;
      The study hypothesis is that we can identify non-invasive predictors of PTL at risk for PTD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN This is a prospective study involving a cohort of pregnant subjects with&#xD;
      pre-term labor. Maternal blood and cervical/vaginal fluid will be collected from consenting&#xD;
      subjects with preterm labor. Repeat sampling of cervical fluid will occur as often as weekly&#xD;
      until the time of delivery. Relevant clinical and demographic data will be recorded. Levels&#xD;
      of prostaglandins (PG's), lipocalin-type prostaglandin D2 synthase (L-PGDS) and cytokines&#xD;
      will be determined using ELISA. DNA will also be extracted from maternal blood for SNP&#xD;
      analysis of cytokine genes. At the time of delivery, cord blood and placenta samples will be&#xD;
      collected if logistically possible (during regular laboratory hours). To determine fetal&#xD;
      levels of PG's, L-PGDS and cytokines in cord blood will be analyzed using ELISA. Placental&#xD;
      samples will be used for in vitro studies aimed at investigating the placental regulatory&#xD;
      pathways of cytokine and PG production. Placental samples will also be processed and embedded&#xD;
      in paraffin for use in immunohistochemical studies in order to localize the expression of&#xD;
      PG's and cytokines. Clinical delivery data will also be recorded.&#xD;
&#xD;
      Gender of Subjects. Only female subjects will be included.&#xD;
&#xD;
      Age of Subjects. The age of subjects will be restricted to 18-45 years.&#xD;
&#xD;
      Inclusion Criteria. Women with a diagnosis of preterm labor will be included in this study.&#xD;
      Preterm labor will be diagnosed as&#xD;
&#xD;
      Six or more contractions per hour associated with one of the following:&#xD;
&#xD;
        1. cervical dilation &gt;= 2 cm&#xD;
&#xD;
        2. cervical effacement &gt; 80%&#xD;
&#xD;
        3. documented changes in dilation or effacement&#xD;
&#xD;
      OR Cervical length less than 2.5 cm by ultrasound with or without contractions.&#xD;
&#xD;
      Exclusion Criteria. Multiple pregnancy, fetal anomalies, abruptio placenta, preeclampsia,&#xD;
      cervical dilation greater than 4 cm, clinical signs of infection and vaginal bleeding.&#xD;
&#xD;
      Subject Capacity. All subjects included in this study will have the capacity to give informed&#xD;
      consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Original Principal Investigator, G. Ashmead, MD left the Institution&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>Course of pregnancy</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Preterm delivery (&lt; 37 weeks)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Term delivery (&gt;=37 weeks)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal blood Maternal cervical secretions Fetal umbilical cord blood Placenta&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women ages 18-45 with a diagnosis of preterm labor&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with a diagnosis of preterm labor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancy, fetal anomalies, abruptio placenta, preeclampsia, cervical&#xD;
             dilation greater than 4 cm, clinical signs of infection and vaginal bleeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham G Ashmead, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winthrop-University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Invasive Biomarkers Preterm Delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

